Christoph Stephan

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi request reprint Travel-acquired dengue infection: clinical spectrum and diagnostic aspects
    C Stephan
    Clinic for Internal Medicine, Dept of Infectious Disease, Frankfurt am Main, Germany
    Infection 30:225-8. 2002
  2. ncbi request reprint Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
    Christoph Stephan
    Division of Infectious Disease, and Institute of Clinical Pharmacology, Pharma Center, JW Goethe University Hospital, Frankfurt, Germany
    AIDS 18:503-8. 2004
  3. ncbi request reprint Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient
    Christoph Stephan
    AIDS 18:1613-4. 2004
  4. ncbi request reprint Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus
    Christoph Stephan
    HIV Research and Treatment Unit at Center for Internal Medicine, Johann Wolfgang Goethe University Hospital Frankfurt, Germany
    J Antimicrob Chemother 56:1087-93. 2005
  5. ncbi request reprint The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
    Schlomo Staszewski
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 58:1024-30. 2006
  6. doi request reprint Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*
    C Stephan
    Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    HIV Med 14:284-92. 2013
  7. doi request reprint Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy
    Christoph Stephan
    Infectious Diseases Unit at Medical Department No 2, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Med Microbiol Immunol 202:117-24. 2013
  8. doi request reprint Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature
    Christoph Stephan
    Johann Wolfgang Goethe University Hospital Frankfurt, Germany Center for Internal Medicine, Infectious Diseases Unit, Theodor Stern Kai 7, Frankfurt, Germany
    Expert Opin Pharmacother 13:2355-67. 2012
  9. ncbi request reprint [Leptospirosis after a staff outing]
    C Stephan
    Schwerpunkt Infektiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Dtsch Med Wochenschr 125:623-7. 2000
  10. doi request reprint [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]
    Christoph Stephan
    Schwerpunkt Therapie der HIV Infektion, Zentrum der Inneren Medizin, Klinik 2 Hämatologie Onkologie, Rheumatologie und Infektiologie, Klinikum der Johann Wolfgang Goethe Universität Frankfurt Main, Frankfurt Main
    Med Klin (Munich) 103:69-74. 2008

Detail Information

Publications31

  1. ncbi request reprint Travel-acquired dengue infection: clinical spectrum and diagnostic aspects
    C Stephan
    Clinic for Internal Medicine, Dept of Infectious Disease, Frankfurt am Main, Germany
    Infection 30:225-8. 2002
    ..Only few studies focus on clinical manifestations and serological findings in primarily nonimmune individuals...
  2. ncbi request reprint Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
    Christoph Stephan
    Division of Infectious Disease, and Institute of Clinical Pharmacology, Pharma Center, JW Goethe University Hospital, Frankfurt, Germany
    AIDS 18:503-8. 2004
    ..To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir...
  3. ncbi request reprint Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient
    Christoph Stephan
    AIDS 18:1613-4. 2004
  4. ncbi request reprint Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus
    Christoph Stephan
    HIV Research and Treatment Unit at Center for Internal Medicine, Johann Wolfgang Goethe University Hospital Frankfurt, Germany
    J Antimicrob Chemother 56:1087-93. 2005
    ..We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection...
  5. ncbi request reprint The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
    Schlomo Staszewski
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 58:1024-30. 2006
    ....
  6. doi request reprint Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*
    C Stephan
    Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    HIV Med 14:284-92. 2013
    ..Individual randomized trials of first-line antiretroviral treatment do not consistently show an association between higher baseline HIV-1 RNA and lower efficacy...
  7. doi request reprint Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy
    Christoph Stephan
    Infectious Diseases Unit at Medical Department No 2, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Med Microbiol Immunol 202:117-24. 2013
    ..Viral detection >200 copies/ml was associated with decreasing CD4-cell slopes and emergence of major mutations, supporting this as benchmark for virological failure definition on PI therapy...
  8. doi request reprint Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature
    Christoph Stephan
    Johann Wolfgang Goethe University Hospital Frankfurt, Germany Center for Internal Medicine, Infectious Diseases Unit, Theodor Stern Kai 7, Frankfurt, Germany
    Expert Opin Pharmacother 13:2355-67. 2012
    ..Patients on antiretroviral combination therapy, experiencing drug toxicity or inconvenience, require alternative options maintaining virological suppression. The protease inhibitor atazanavir is a promising candidate...
  9. ncbi request reprint [Leptospirosis after a staff outing]
    C Stephan
    Schwerpunkt Infektiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Dtsch Med Wochenschr 125:623-7. 2000
    ..About 18 days before they had been together on a boat rafting tour when the boat capsized when they had fallen into a river in high flood...
  10. doi request reprint [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]
    Christoph Stephan
    Schwerpunkt Therapie der HIV Infektion, Zentrum der Inneren Medizin, Klinik 2 Hämatologie Onkologie, Rheumatologie und Infektiologie, Klinikum der Johann Wolfgang Goethe Universität Frankfurt Main, Frankfurt Main
    Med Klin (Munich) 103:69-74. 2008
    ..The purpose of this case-control study was to determine the susceptibility patterns of pneumococci from adult patients in relation to their HIV status and to compare both patient groups...
  11. pmc Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
    C Stephan
    Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur J Med Res 15:369-76. 2010
    ..This analysis presents data from the German subgroup of protease inhibitor (PI)-pretreated, but SQV-naive patients...
  12. ncbi request reprint Dose reduction effective in alleviating symptoms of saquinavir toxicity
    C Stephan
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Department of Internal Medicine II, Frankfurt, Germany
    Int J STD AIDS 18:81-4. 2007
    ..Although delayed autoinduction is not well established as a reason for adverse events in saquinavir therapy, this observation may be confirmed in the near future by increased use...
  13. doi request reprint Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country
    Christoph Stephan
    HIVCENTER at Medical Department II, Hospital of Johann Wolfgang Goethe University, Frankfurt, Germany
    AIDS 22:2471-9. 2008
    ..To evaluate the interferon-gamma-releasing assays QuantiFERON-tuberculosis (TB) Gold and T-SPOT.TB in addition to tuberculin skin test (TST) for diagnosis of latent tuberculosis infection in HIV patients...
  14. doi request reprint Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R
    C Stephan
    HIVCENTER, Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Theodor Stern Kai 7, Frankfurt, Germany
    J Infect 61:346-50. 2010
    ..The reverse transcriptase (RT)-mutation K65R limits further therapeutic options and has been selected by unfavorable RT-combinations, e.g. tenofovir in combination with abacavir and/or didanosine...
  15. ncbi request reprint Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Christoph Stephan
    Johann Wolfgang Goethe University Hospital, HIV Treatment and Clinical Research Unit, Medical Department II, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Curr HIV Res 7:320-6. 2009
    ..We investigated the virologic and immunologic responses to a mono-class, nucleoside/nucleotide reverse transcriptase inhibitor - combination therapy consisting of tenofovir and zidovudine/lamivudine/abacavir in therapy experienced patients...
  16. pmc Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 52:2273-5. 2008
    ..Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised...
  17. ncbi request reprint Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Antivir Ther 13:1039-46. 2008
    ....
  18. doi request reprint Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany
    Clin Infect Dis 52:122-7. 2011
    ..gov NCT01017172)...
  19. doi request reprint Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
    Annette Haberl
    HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 66:375-81. 2010
    ..We performed a matched-pairs analysis on 24 patients (12 men/women) taking atazanavir/ritonavir 300/100 mg daily plus reverse transcriptase inhibitors, with (n = 12) or without (n = 12) methadone co-administration...
  20. pmc Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes
    Martin Stürmer
    Johann Wolfgang Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
    Antimicrob Agents Chemother 55:5362-6. 2011
    ..Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than "natural resistance."..
  21. doi request reprint Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Frankfurt, Germany
    AIDS 24:F31-5. 2010
    ..To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172)...
  22. ncbi request reprint Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis
    Markus Bickel
    HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    Scand J Infect Dis 37:520-2. 2005
    ..Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy...
  23. doi request reprint Experience with tenofovir disoproxil fumarate for antiretroviral therapy
    Christoph Stephan
    Hospital of the Johann Wolfgang Goethe University, Internal Medicine and Infectious Diseases, Medical HIV Treatment and Research Unit, Department of Internal Medicine II, Frankfurt, Germany
    Expert Opin Pharmacother 9:1197-209. 2008
    ..This article describes the efficacy and safety of tenofovir disoproxil fumarate from ongoing and recent clinical trials, and key aspects of its broad, clinical experience since its introduction...
  24. ncbi request reprint The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load
    M Bickel
    Department of Infectious Disease, HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 6:179-84. 2005
    ....
  25. doi request reprint Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls
    Markus Bickel
    Department of Infectious Disease, JW Goethe University, Frankfurt, Germany
    HIV Clin Trials 14:175-81. 2013
    ..Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients...
  26. doi request reprint Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients
    M Bickel
    HIVCENTER, JW Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    J Antimicrob Chemother 64:1260-4. 2009
    ..To investigate the feasibility and pharmacokinetics of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir...
  27. ncbi request reprint Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis
    M W Lorenz
    Johann Wolfgang Goethe University Hospital, Department of Neurology, Frankfurt am Main, Germany
    Atherosclerosis 196:720-6. 2008
    ..We investigated the relationship between HIV infection, antiretroviral medication and ultrasound evidence of early atherosclerosis in the context of vascular risk factors...
  28. ncbi request reprint Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects
    G Just-Nübling
    Dept of Infectiology, Medical Clinic III, J W Goethe University Hospital, Theodor Stern Kai 7, D 60590, Frankfurt am Main, Germany
    Infection 31:318-23. 2003
    ..Occasionally, primary cytomegalovirus (CMV) infection may give rise to more or less severe clinical illness in immunocompetent adults. We retrospectively analyzed cases of acute CMV infection in medical outpatients...
  29. pmc Renal AA-amyloidosis in intravenous drug users--a role for HIV-infection?
    Oliver Jung
    Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
    BMC Nephrol 13:151. 2012
    ..Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades...
  30. ncbi request reprint A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy
    M Bickel
    HIV Medical Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 8:413-9. 2007
    ..Although multiple methods have been proposed, there is no current gold standard for assessing HIV-1-associated lipodystrophy...
  31. ncbi request reprint Winterbottom's sign and hypertrophic cardiomyopathy
    Christoph Stephan
    Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Scand J Infect Dis 34:544-5. 2002
    ..He made a full recovery after intravenous administration of eflornithine, a drug that is no longer distributed for antiparasitic indications for pharmacoeconomic reasons...